glp 1 dementia prevention Are GLP‑1 Meds the Next Frontier in Prevention? GLP-1 and the Degenerating Brain:

2015;86:S2239253X15023701

: increase

Results showed that GLP-1 receptor agonists and SGLT2 inhibitors were superior in reducing the risk of MACE when compared to DPP-4 inhibitors (HR 086 [082089] and 086 [082090], respectively), but no difference was found between SGLT2 inhibitors and GLP-1 receptor agonists in reducing rate of MACE (HR of 101 (094107)) (68)

pmid:17655880 21

Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights including FTO, GLP1R, MC4R, and TCF7L2 markers that shape your GLP-1, appetite-regulation, and energy-balance biology